AstraZeneca PLC' s confirmation that the closely-watched MYSTIC lung cancer trial of Imfinzi (durvalumab) has failed has disappointed investors but the company is keeping faith with the PD-L1 inhibitor and tremelimumab in other NSCLC trials.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?